Abstract
Serelaxin is a novel recombinant form of human vasoactive peptide relaxin-2. The international randomized RELAX-AHF trial compared serelaxin with placebo in patiens hospitalized for acute heart failure.
Serelaxin improved primary endpoint - the visual analogue scale area under the curve of patient-reported dyspnoea compared to placebo. There was no significant difference between placebo and serelaxin for the second primary endpoint - Likert scale, measuring proportion of patients with dyspnoea improvement.
Serelaxin improved some other symptoms of heart decompensation. The secondary efficacy endpoints of cardiovascular mortality or rehospitalization for heart or renal failure at 60 days were not significantly improved.
Surprisingly, serelaxin therapy decreased cardiovascular and all-cause mortality at 180 days.